Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Explore the Immunogenicity of the Tuberculosis (TB) Vaccine Candidate QTP101 (ID93+GLA-SE) in Older Adults (Aged 55~74 Years)
NCT06714513 is registered in ClinicalTrials.gov with Quratis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Explore the Immunogenicity of the Tuberculosis (TB) Vaccine Candidate QTP101 (ID93+GLA-SE) in Older Adults (Aged 55~74 Years)
- Lead sponsor
- Quratis Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 9, 2025
- Completion date
- December 31, 2026
- Enrollment
- 144 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.